Clinical trials demonstrate significant weight reduction, with patients losing approximately 15% of body weight over 68 weeks with semaglutide (STEP 1 trial) and up to 21% with tirzepatide 15 mg over 72 weeks (SURMOUNT-1 trial)
Should we be cautious on the use of commercially available antibodies to dopamine receptors
Long gone are the days of overdosing products in an attempt to improve our bodies ability to utilize as much of the ingredient as possible without being destroyed by our digestive track or liver
SlimSEB: Clinically Studied Metabolic Support Whether youre developing a GLP-1 companion product or a non-pharmaceutical alternative, SlimSEB provides a science-backed solution
InjectCos compounded semaglutide program includes comprehensive medical support, making it both affordable and safe
Thirdly, gastrointestinal side effects such as nausea, vomiting, and diarrhoea can indirectly affect cognition through multiple pathways